{
    "nct_id": "NCT03568461",
    "official_title": "A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Efficacy and Safety of Tisagenlecleucel (CTL019) in Adult Patients With Refractory or Relapsed Follicular Lymphoma",
    "inclusion_criteria": "* Refractory or relapsed Follicular Lymphoma (Grade 1, 2, 3A)\n* Radiographically measurable disease at screening\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 100 Years",
    "exclusion_criteria": "* Evidence of histologic transformation\n* Follicular Lymphoma Grade 3B\n* Prior anti-CD19 therapy\n* Prior gene therapy\n* Prior adoptive T cell therapy\n* Prior allogeneic hematopoietic stem cell transplant\n* Active CNS involvement by malignancy\n\nOther protocol-defined Inclusion/Exclusion criteria may apply.",
    "miscellaneous_criteria": ""
}